Charles River Laboratories
CRL
560 hedge funds and large institutions have $8.03B invested in Charles River Laboratories in 2025 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 188 increasing their positions, 244 reducing their positions, and 132 closing their positions.
0.83% more ownership
Funds ownership: 103.62% → 104.46% (+0.83%)
12% less funds holding
Funds holding: 635 → 560 (-75)
16% less call options, than puts
Call options by funds: $106M | Put options by funds: $125M
20% less capital invested
Capital invested by funds: $10B → $8.03B (-$1.98B)
23% less repeat investments, than reductions
Existing positions increased: 188 | Existing positions reduced: 244
49% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 132
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$345M |
| 2 |
Goldman Sachs
New York
|
+$134M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$90.3M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$79.2M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$59.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Koshinski Asset Management
Decatur,
Illinois
|
-$234M |
| 2 |
MG
Meritage Group
San Francisco,
California
|
-$198M |
| 3 |
SCA
Southpoint Capital Advisors
New York
|
-$111M |
| 4 |
BlackRock
New York
|
-$94.1M |
| 5 |
MDSL
M.D. Sass LLC
New York
|
-$72.3M |
CRL Hedge Fund Activity: Q1 2025 in Review
560 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2025, worth a combined $8.03B — down 20% from $10B a quarter earlier.
Sellers outnumbered buyers: 132 funds closed out of CRL and 67 opened new positions — a net loss of 65 holders — while 244 trimmed existing stakes and 188 added.
The largest buyer was UBS Group, adding an estimated $345M. The largest seller was Koshinski Asset Management, exiting entirely with an estimated $234M sold.
- 560 institutional investors held Charles River Laboratories (CRL) as of Q1 2025, down from 635 in Q4 2024.
- Funds reported $8.03B of Charles River Laboratories stock for Q1 2025, down 20% quarter-over-quarter.
- 67 funds opened new Charles River Laboratories positions in Q1 2025 and 132 closed out, a net change of -65 holders.
- The largest Charles River Laboratories buyer in Q1 2025 was UBS Group, an estimated $345M added.
- The largest Charles River Laboratories seller in Q1 2025 was Koshinski Asset Management, an estimated $234M sold.
Based on aggregated 13F filings for Q1 2025.